Genova Diagnostics has entered a strategic partnership with Neurocode to launch its p-Tau217 blood biomarker test for the early detection of Alzheimer’s disease.
The Alzheimer’s Assessment is a blood test that uses the phosphorylated tau at position 217 (p-Tau217) biomarker to detect Alzheimer’s disease before the appearance of any clinical symptoms. Early disease detection allows for earlier intervention and management.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“Offering the pTau217 biomarker through a partnership with Genova Diagnostics gives drastic accessibility to a larger segment of people that can now monitor amyloid activity in their brains with a simple blood draw,” said Roopa Reddy, CEO at Neurocode.
Neurocore already has a Tau blood biomarker test for detecting Alzheimer’s. In March, the company debuted ALZpath Dx, a blood test that measures levels of pTau217.
The use of Tau biomarkers in blood to screen and detect Alzheimer’s is becoming much more widely accepted in the field, as a result, multiple companies are developing diagnostic blood tests based on this. GlobalData expects the Alzheimer’s disease market to be worth $15.9bn globally by 2030, with more than 70 in vitro diagnostics for Alzheimer’s currently in development.
Last month, Biogen, Beckman Coulter and Fujirebio shared their plans to identify and develop new blood-based biomarkers for Tau pathology. As part of the agreement, Biogen will provide Alzheimer’s clinical study data and biomarker research expertise to prioritise tau pathology markers. While Fujirebio and Beckman Coulter will be responsible for diagnostic development, manufacturing, and commercialisation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataC2N Diagnostics has developed a PrecivityAD2 blood test that can be used to screen for Alzheimer’s disease in primary care settings. The test uses high-resolution mass spectrometry to precisely measure proteins, which are then analysed using a validated algorithm to predict the likelihood of the presence of brain amyloid pathology.
In April, Roche secured a breakthrough device designation from the US Food and Drug Administration for its Elecsys pTau217 plasma biomarker assay. In March, Labcorp launched a pTau217 blood biomarker test.
